TXMD News and Press, TherapeuticsMD Inc. From 11/03/21

Are These Penny Stocks A Buy Or Avoid Right Now? If you’re like most retail traders right now, you’re on the hunt for the next round of hot penny stocks to buy. In the stock market today, meme stocks are heating up. What some may consider the “OG” or bell...

-Executive Management to Host Conference Call on November 11, 2021 at 8:30 a.m. ET- TherapeuticsMD, Inc. (NASDAQ: TXMD) (“TXMD” or the “Company”), an innovative, leading women’s healthcare company, today announced that it will report its third ...

TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Mark Glickman as the Company’s Chief Business Officer. Mr. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceu...

September is Menopause Awareness month, and TherapeuticsMD aims to de-stigmatize and provide education every woman should know about menopause In the next ten years, there will be more than 1.2 billion women worldwide in menopause i More than 80% of women experienc...

Locust Walk Acquisition (NASDAQ:LWAC) announces business combination with eFFECTOR Therapeutics (NASDAQ:TXMD). The business combination is expected to close on or about Wednesday, August 25, 2021. The combined company expects will commence trading on Nasdaq under the new tradin...

CMS has established new HCPCS Level II code J7294 to be effective October 1 st , 2021 J Code will provide dispensing Title X Family Planning clinics such as Planned Parenthood facilities with the ability to get reimbursed for dispensing ANNOVERA TherapeuticsMD, I...

– O’Dowd brings 25+ years of experience in senior leadership roles with leading pharmaceutical companies – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the appointment of Hugh O’Dowd as...

The following slide deck was published by TherapeuticsMD, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: TherapeuticsMD, Inc. 2021 Q2 - Results - Earnings Call Presentation

TherapeuticsMD, Inc. (TXMD) Q2 2021 Earnings Conference Call August 4, 2021 8:30 AM ET Company Participants Lisa Wilson – Investor Relations Rob Finizio – Chief Executive Officer James D’Arecca – Chief Financial Officer Dawn Halkuff – Chief Commercial Office...

- 2Q21 total net product revenue increased by 17% over 1Q21 to $23 million - - ANNOVERA ® prescription growth supported by improved access to providers and increased telemedicine options for patients - - Prescriptions for IMVEXXY® grew by 8% over 1Q21, outpacing th...